These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25801554)

  • 1. Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.
    te Brake LH; Ruslami R; Later-Nijland H; Mooren F; Teulen M; Apriani L; Koenderink JB; Russel FG; Burger DM; Alisjahbana B; Wieringa F; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2015; 59(6):3233-9. PubMed ID: 25801554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of standard versus high-dose rifampin for tuberculosis preventive treatment: A sub-study of the 2R
    Gafar F; Yunivita V; Fregonese F; Apriani L; Aarnoutse RE; Ruslami R; Menzies D
    Int J Antimicrob Agents; 2024 Jul; 64(1):107197. PubMed ID: 38750674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status.
    Dayal R; Singh Y; Agarwal D; Kumar M; Swaminathan S; Ramachandran G; Kumar S; Narayan S; Goyal A; Kumar AKH
    Arch Dis Child; 2018 Dec; 103(12):1150-1154. PubMed ID: 29514812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients.
    Requena-Méndez A; Davies G; Waterhouse D; Ardrey A; Jave O; López-Romero SL; Ward SA; Moore DA
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7164-70. PubMed ID: 25224007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.
    Sturkenboom MG; Mulder LW; de Jager A; van Altena R; Aarnoutse RE; de Lange WC; Proost JH; Kosterink JG; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4907-13. PubMed ID: 26055359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.
    Nijland HM; Ruslami R; Stalenhoef JE; Nelwan EJ; Alisjahbana B; Nelwan RH; van der Ven AJ; Danusantoso H; Aarnoutse RE; van Crevel R
    Clin Infect Dis; 2006 Oct; 43(7):848-54. PubMed ID: 16941365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes.
    Ruslami R; Nijland HM; Adhiarta IG; Kariadi SH; Alisjahbana B; Aarnoutse RE; van Crevel R
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1068-74. PubMed ID: 20038625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis.
    Perlman DC; Segal Y; Rosenkranz S; Rainey PM; Remmel RP; Salomon N; Hafner R; Peloquin CA;
    Clin Infect Dis; 2005 Dec; 41(11):1638-47. PubMed ID: 16267738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis.
    Dian S; Yunivita V; Ganiem AR; Pramaesya T; Chaidir L; Wahyudi K; Achmad TH; Colbers A; Te Brake L; van Crevel R; Ruslami R; Aarnoutse R
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants.
    Egelund EF; Isaza R; Brock AP; Alsultan A; An G; Peloquin CA
    J Vet Pharmacol Ther; 2015 Apr; 38(2):137-43. PubMed ID: 25236765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV.
    Jeremiah K; Denti P; Chigutsa E; Faurholt-Jepsen D; PrayGod G; Range N; Castel S; Wiesner L; Hagen CM; Christiansen M; Changalucha J; McIlleron H; Friis H; Andersen AB
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3468-74. PubMed ID: 24709267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.
    Medellín-Garibay SE; Cortez-Espinosa N; Milán-Segovia RC; Magaña-Aquino M; Vargas-Morales JM; González-Amaro R; Portales-Pérez DP; Romano-Moreno S
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7707-14. PubMed ID: 26438503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study.
    Zentner I; Schlecht HP; Khensouvann L; Tamuhla N; Kutzler M; Ivaturi V; Pasipanodya JG; Gumbo T; Peloquin CA; Bisson GP; Vinnard C
    BMC Infect Dis; 2016 Jun; 16():242. PubMed ID: 27250739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.